PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model
Jamal Alzubi, Viviane Dettmer‐Monaco, Johannes Kuehle, Niko Thorausch, Maximilian Seidl, Sanaz Taromi, Wolfgang W. Schamel, Robert Zeiser, Hinrich Abken, Toni Cathomen, Philipp Wolf
Abstract
, focal injections of the PSMA CAR T cells eradicated established human prostate cancer xenografts in a preclinical mouse model. Moreover, systemic intravenous CAR T cell application significantly inhibited tumor growth in combination with non-ablative low-dose docetaxel chemotherapy, while docetaxel or CAR T cell application alone was not effective. In conclusion, the focal application of D7-derived CAR T cells and their combination with chemotherapy represent promising immunotherapeutic avenues to treat local and advanced prostate cancer in the clinic.
Topics & Concepts
DocetaxelProstate cancerMedicineOncologyCancer researchInternal medicineCancerCAR-T cell therapy researchViral Infectious Diseases and Gene Expression in InsectsVirus-based gene therapy research